Showing 13 to 15 of 15 results
Lenacapavir: A Highly Effective but Expensive HIV Drug
Lenacapavir, a new HIV drug from Gilead, offers near-100% efficacy with twice-yearly injections but faces accessibility challenges due to its $40,000 annual cost, although Gilead is negotiating lower prices in 120 low-income countries.
Lenacapavir: A Highly Effective but Expensive HIV Drug
Lenacapavir, a new HIV drug from Gilead, offers near-100% efficacy with twice-yearly injections but faces accessibility challenges due to its $40,000 annual cost, although Gilead is negotiating lower prices in 120 low-income countries.
Progress
60% Bias Score
Injectable HIV PrEP Shows 96% Infection Reduction
Lenacapavir, a new injectable HIV PrEP medication, demonstrated 96% infection reduction compared to daily Truvada in clinical trials, offering improved convenience and addressing stigma, though high cost remains a concern.
Injectable HIV PrEP Shows 96% Infection Reduction
Lenacapavir, a new injectable HIV PrEP medication, demonstrated 96% infection reduction compared to daily Truvada in clinical trials, offering improved convenience and addressing stigma, though high cost remains a concern.
Progress
48% Bias Score
Semiannual HIV Injection Shows High Efficacy, Poses Access Challenges
A Phase 3 trial shows Lenacapavir, a semiannual HIV prevention injection, is highly effective and comparable to daily Truvada, offering improved adherence and reducing stigma in high-prevalence regions, but its high cost poses a global access challenge.
Semiannual HIV Injection Shows High Efficacy, Poses Access Challenges
A Phase 3 trial shows Lenacapavir, a semiannual HIV prevention injection, is highly effective and comparable to daily Truvada, offering improved adherence and reducing stigma in high-prevalence regions, but its high cost poses a global access challenge.
Progress
40% Bias Score
Showing 13 to 15 of 15 results